企業プロフィール
Phathom Pharmaceuticals 株価・ニュース・カタリスト
- ティッカー:
- PHAT
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
9.28 USD (-3.13%)
終値
最終更新: 2026年8月17日
770M USD
時価総額
株価変動の要因
As of Aug 17, 2026, PHAT closed down 3.13% at $9.28. No new same-company headline was identified in the current news window.
企業概要
Gastrointestinal Medicines
Phathom Pharmaceuticals develops and commercializes treatments for acid-related gastrointestinal diseases. It holds U.S., European and Canadian rights to vonoprazan, a potassium-competitive acid blocker.
VOQUEZNA Franchise
VOQUEZNA is marketed in the United States for heartburn associated with non-erosive gastroesophageal reflux disease, healing and maintenance of erosive GERD, and as dual- or triple-drug packs for Helicobacter pylori infection. Its mechanism provides rapid and durable acid suppression distinct from proton-pump inhibitors.
Eosinophilic Esophagitis Development
The Phase 2 pHalcon-EoE-201 trial is evaluating VOQUEZNA in eosinophilic esophagitis. This program tests whether strong acid suppression can benefit a chronic inflammatory esophageal disease and extend the franchise into another specialist-treated indication.
今後のカタリスト
- Topline results from the Phase 2 pHalcon-EoE-201 trial expected in late fourth-quarter 2026 or early first-quarter 2027.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。